Indications and safety of intravenous and subcutaneous immunoglobulin therapy

References

• Cunningham-Rundles C. Lung disease, antibodies and other unresolved issues in immune globulin therapy for antibody deficiency. Clin. Exp. Immunol.157(Suppl. 1), S12–S16 (2009).
   PubMedGoogle Scholar
• Radosevich M, Burnouf T. Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox. Sang.98(1), 12–28 (2010).
   PubMed Web of Science ®Google Scholar
• Garcia-Lloret M, McGhee S, Chatila TA. Immunoglobulin replacement therapy in children. Immunol. Allergy Clin. North Am.28(4), 833–849, ix (2008).
   PubMed Web of Science ®Google Scholar
• Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol. Allergy Clin. North Am.28(2), 413–437, x (2008).
   PubMed Web of Science ®Google Scholar
• Toubi E, Etzioni A. Intravenous immunoglobulin in immunodeficiency states: state of the art. Clin. Rev. Allergy Immunol.29(3), 167–172 (2005).
   PubMedGoogle Scholar
• Eibl MM. History of immunoglobulin replacement. Immunol. Allergy Clin. North Am.28(4), 737–764, viii (2008).
   PubMed Web of Science ®Google Scholar
• Bruton OC. Agammaglobulinemia. Pediatrics9(6), 722–728 (1952).
   PubMed Web of Science ®Google Scholar
• Berger M. A history of immune globulin therapy, from the Harvard crash program to monoclonal antibodies. Curr. Allergy Asthma Rep.2(5), 368–378 (2002).
   PubMedGoogle Scholar
• Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human gamma-globulin. Vox. Sang.7, 157–174 (1962).
   PubMed Web of Science ®Google Scholar
• Looney RJ, Huggins J. Use of intravenous immunoglobulin G (IVIg). Best Pract. Res. Clin. Haematol.19(1), 3–25 (2006).
   PubMed Web of Science ®Google Scholar
• Orange JS, Hossny EM, Weiler CR et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J. Allergy Clin. Immunol.117(4 Suppl.), S525–S553 (2006).
   PubMed Web of Science ®Google Scholar
• Imbach P, Barandun S, Baumgartner C, Hirt A, Hofer F, Wagner HP. High-dose intravenous gammaglobulin therapy of refractory, in particular idiopathic thrombocytopenia in childhood. Helv. Paediatr. Acta36(1), 81–86 (1981).
   PubMedGoogle Scholar
• McDaneld LM, Fields JD, Bourdette DN, Bhardwaj A. Immunomodulatory therapies in neurologic critical care. Neurocrit. Care12(1), 132–143 (2010).
   PubMedGoogle Scholar
• Arnson Y, Shoenfeld Y, Amital H. Intravenous immunoglobulin therapy for autoimmune diseases. Autoimmunity42(6), 553–560 (2009).
   PubMed Web of Science ®Google Scholar
• Chouksey A, Duff K, Wasserbauer N, Berger M. Subcutaneous immunoglobulin-G replacement therapy with preparations currently available in the United States for intravenous or intramuscular use: reasons and regimens. Allergy Asthma Clin. Immunol.1(3), 120–130 (2005).
   PubMedGoogle Scholar
• Remvig L, Andersen V, Hansen NE, Karle H. Prophylactic effect of self-administered pump-driven subcutaneous IgG infusion in patients with antibody deficiency: a triple-blind cross-over study comparing P-IgG levels of 3 g l-1 versus 6 g l-1. J. Intern. Med.229(1), 73–77 (1991).
   PubMedGoogle Scholar
• Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J. Clin. Immunol.30(2), 301–307 (2010).
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Bellon B, Kaveri SV. Mechanisms of action of intravenous immunoglobulin (IVIg). Mult. Scler.6(Suppl. 2), S24–S26; discussion S33 (2000).
   PubMedGoogle Scholar
• Simon HU, Spath PJ. IVIg – mechanisms of action. Allergy58(7), 543–552 (2003).
   PubMed Web of Science ®Google Scholar
• Terness P, Opelz G. Natural anti-immunoglobulin autoantibodies: irrelevant by-products or immunoregulatory molecules? Int. Arch. Allergy Immunol.115(4), 270–277 (1998).
   PubMedGoogle Scholar
• Cukrowska B, Sinkora J, Mandel L et al. Thymic B cells of pig fetuses and germ-free pigs spontaneously produce IgM, IgG and IgA: detection by ELISPOT method. Immunology87(3), 487–492 (1996).
   PubMedGoogle Scholar
• Provan D, Nokes TJC, Agrawal S, Winer J, Wood P. Clinical Guidelines for Immunoglobulin Use (2nd Edition). NHS, London, UK (2008).
   Google Scholar
• Sewell C. First National Immunoglobulin Database Report (2008–2009). NHS, London, UK (2010).
   Google Scholar
• Gurcan HM, Keskin DB, Ahmed AR. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun. Rev.9(8), 553–559 (2010).
   PubMed Web of Science ®Google Scholar
• El-Shanawany T, Sewell WA, Misbah SA, Jolles S. Current clinical uses of intravenous immunoglobulin. Clin. Med.6(4), 356–359 (2006).
   PubMed Web of Science ®Google Scholar
• Hull JZ, Hull JH. Current clinical uses of intravenous immunoglobulin. Clin. Med.6(5), 507; author reply 507–508 (2006).
   PubMedGoogle Scholar
• Jolles S, Sewell WA, Misbah SA. Clinical uses of intravenous immunoglobulin. Clin. Exp. Immunol.142(1), 1–11 (2005).
   PubMed Web of Science ®Google Scholar
• Shimoni Z, Bulvik S, Niveni M. Current clinical uses of intravenous immunoglobulin. Clin. Med.6(6), 621; author reply 621–622 (2006).
   PubMedGoogle Scholar
• Lucas M, Lee M, Lortan J, Lopez-Granados E, Misbah S, Chapel H. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J. Allergy Clin. Immunol.125(6), 1354–1360; e1354 (2010).
   PubMed Web of Science ®Google Scholar
• Lederman HM, Roifman CM, Lavi S, Gelfand EW. Corticosteroids for prevention of adverse reactions to intravenous immune serum globulin infusions in hypogammaglobulinemic patients. Am. J. Med.81(3), 443–446 (1986).
   PubMed Web of Science ®Google Scholar
• Mouthon L. Indications for intravenous immunoglobulins. Presse. Med.35(4 Pt 2), 714–719 (2006).
   PubMedGoogle Scholar
• Aghamohammadi A, Farhoudi A, Moin M et al. Adverse effects of intravenous immunoglobulin therapy in patients with antibody deficiency. Iran. J. Allergy Asthma Immunol.2(3), 121–126 (2003).
   PubMedGoogle Scholar
• Dashti-Khavidaki S, Aghamohammadi A, Farshadi F et al. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases. J. Investig. Allergol. Clin. Immunol.19(2), 139–145 (2009).
   PubMed Web of Science ®Google Scholar
• Bednarik J, Kadanka Z. Adverse effects of administration of intravenous human immunoglobulins. Cas. Lek. Cesk.138(21), 647–649 (1999).
   PubMedGoogle Scholar
• Schiavotto C, Ruggeri M, Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica78(6 Suppl. 2), 35–40 (1993).
   PubMedGoogle Scholar
• Wittstock M, Zettl UK. Adverse effects of treatment with intravenous immunoglobulins for neurological diseases. J. Neurol.253(Suppl. 5), V75–V79 (2006).
   PubMed Web of Science ®Google Scholar
• Wu KH, Wu WM, Lu MY, Chiang BL. Inhibitory effect of pooled human immunoglobulin on cytokine production in peripheral blood mononuclear cells. Pediatr. Allergy Immunol.17(1), 60–68 (2006).
   PubMedGoogle Scholar
• Pierce LR, Jain N. Risks associated with the use of intravenous immunoglobulin. Transfus. Med. Rev.17(4), 241–251 (2003).
   PubMed Web of Science ®Google Scholar
• Shah SR. A newer immunoglobulin intravenous (IGIV) – gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care. Expert Opin. Biol. Ther.8(6), 799–804 (2008).
   PubMed Web of Science ®Google Scholar
• Katz U, Achiron A, Sherer Y, Shoenfeld Y. Safety of intravenous immunoglobulin (IVIg) therapy. Autoimmun. Rev.6(4), 257–259 (2007).
   PubMed Web of Science ®Google Scholar
• Boger RH, Bode-Boger SM, Frolich JC. Intravenous immunoglobulins. Basic principles, selection criteria and indications for preventive and therapeutic administration. Med. Klin. (Munich)90(9), 520–526 (1995).
   PubMedGoogle Scholar
• Nydegger UE. Safety and side effects of i.v. immunoglobulin therapy. Clin. Exp. Rheumatol.14(Suppl. 15), S53–S57 (1996).
   PubMedGoogle Scholar
• Aghamohammadi A, Moin M, Farhoudi A et al. Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol. Med. Microbiol.40(2), 113–118 (2004).
   PubMed Web of Science ®Google Scholar
• Kanegane H, Nomura K, Futatani T, Miyawaki T. Intravenous immunoglobulin replacement therapy in X-linked agammaglobulinemia. Nihon Rinsho Meneki Gakkai Kaishi25(4), 337–343 (2002).
   PubMedGoogle Scholar
• Busse PJ, Razvi S, Cunningham-Rundles C. Efficacy of intravenous immunoglobulin in the prevention of pneumonia in patients with common variable immunodeficiency. J. Allergy Clin. Immunol.109(6), 1001–1004 (2002).
   PubMed Web of Science ®Google Scholar
• Pourpak Z, Aghamohammadi A, Sedighipour L et al. Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. J. Microbiol. Immunol. Infect.39(2), 114–120 (2006).
   PubMedGoogle Scholar
• Tcheurekdjian H, Palermo T, Hostoffer R. Quality of life in common variable immunodeficiency requiring intravenous immunoglobulin therapy. Ann. Allergy Asthma Immunol.93(2), 160–165 (2004).
   PubMed Web of Science ®Google Scholar
• Mushiake K, Motoyoshi F, Kondo N, Shimizu H, Orii T. Long-term follow up of patients with common variable immunodeficiency treated with intravenous immunoglobulin: reevaluation of intravenous immunoglobulin replacement therapy. IVIg therapy in CVID. Biotherapy7(2), 101–107 (1993).
   PubMedGoogle Scholar
• Davies EG, Thrasher AJ. Update on the hyper immunoglobulin M syndromes. Br. J. Haematol.149(2), 167–180 (2010).
   PubMed Web of Science ®Google Scholar
• McLean GR, Miller KK, Schrader JW, Junker AK. Biased immunoglobulin G (IgG) subclass production in a case of hyper-IgM syndrome. Clin. Diagn. Lab. Immunol.11(6), 1192–1193 (2004).
   PubMedGoogle Scholar
• Schwartz HJ, Hostoffer RW, McFadden ER Jr, Berger M. The response to intravenous immunoglobulin replacement therapy in patients with asthma with specific antibody deficiency. Allergy Asthma Proc.27(1), 53–58 (2006).
   PubMed Web of Science ®Google Scholar
• Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther. Clin. Risk Manag.6, 1–10 (2010).
   PubMedGoogle Scholar
• de Martino M, Galli L, Azzari C, Zammarchi E, Vierucci A. Effect of different intravenous immunoglobulin regimens on hemorrhages, platelet numbers and volume in a child with Wiskott-Aldrich syndrome. Vox. Sang.67(3), 317–319 (1994).
   PubMedGoogle Scholar
• Litzman J, Jones A, Hann I, Chapel H, Strobel S, Morgan G. Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome. Arch. Dis. Child.75(5), 436–439 (1996).
   PubMed Web of Science ®Google Scholar
• Fontan Casariego G. [Primary immunodeficiencies. Clinical features and variant forms]. Allergol. Immunopathol. (Madr.)29(3), 101–107 (2001).
   PubMedGoogle Scholar
• Buckley RH. B-cell function in severe combined immunodeficiency after stem cell or gene therapy: a review. J. Allergy Clin. Immunol.125(4), 790–797 (2010).
   PubMed Web of Science ®Google Scholar
• Kobrynski LJ. Combined immune deficiencies in children. J. Infus. Nurs.29(4), 206–213 (2006).
   PubMedGoogle Scholar
• Minegishi Y, Saito M, Tsuchiya S et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature448(7157), 1058–1062 (2007).
   PubMed Web of Science ®Google Scholar
• Renner ED, Rylaarsdam S, Anover-Sombke S et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(h)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J. Allergy Clin. Immunol.122(1), 181–187 (2008).
   PubMed Web of Science ®Google Scholar
• Sheerin KA, Buckley RH. Antibody responses to protein, polysaccharide, and phi X174 antigens in the hyperimmunoglobulinemia E (hyper-IgE) syndrome. J. Allergy Clin. Immunol.87(4), 803–811 (1991).
   PubMedGoogle Scholar
• DeWitt CA, Bishop AB, Buescher LS, Stone SP. Hyperimmunoglobulin E syndrome: two cases and a review of the literature. J. Am. Acad. Dermatol.54(5), 855–865 (2006).
   PubMed Web of Science ®Google Scholar
• Waldfahrer F, Pahl S, Federspil PA, Iro H. Hyper-IgE syndrome with ENT manifestations. Overview and case report of successful therapy with high dosage i.v. immunoglobulin. HNO47(12), 1063–1068 (1999).
   PubMedGoogle Scholar
• Sun JD, Linden KG. Netherton syndrome: a case report and review of the literature. Int. J. Dermatol.45(6), 693–697 (2006).
   PubMedGoogle Scholar
• Renner ED, Hartl D, Rylaarsdam S et al. Comel-Netherton syndrome defined as primary immunodeficiency. J. Allergy Clin. Immunol.124(3), 536–543 (2009).
   PubMed Web of Science ®Google Scholar
• Boughton BJ, Jackson N, Lim S, Smith N. Randomized trial of intravenous immunoglobulin prophylaxis for patients with chronic lymphocytic leukaemia and secondary hypogammaglobulinaemia. Clin. Lab. Haematol.17(1), 75–80 (1995).
   PubMedGoogle Scholar
• Chapel HM, Hargreaves R, Lee M, Pamphilon D. Intravenous immunoglobulin therapy in patients with multiple myeloma. Immunodeficiency4(1–4), 77–78 (1993).
   PubMedGoogle Scholar
• Sokos DR, Berger M, Lazarus HM. Intravenous immunoglobulin: appropriate indications and uses in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant.8(3), 117–130 (2002).
   PubMed Web of Science ®Google Scholar
• Khouri IF, Ippoliti C, Gajewski J, Przepiorka D, Champlin RE. Neutropenias following allogeneic bone marrow transplantation: response to therapy with high-dose intravenous immunoglobulin. Am. J. Hematol.52(4), 313–315 (1996).
   PubMedGoogle Scholar
• Nasman Bjork I, Fesel C, Brissac C, Lundkvist I. Prophylactic intravenous immunoglobulin treatment influences serum immunoglobulin M repertoire development after allogeneic bone marrow transplantation. Scand. J. Immunol.50(1), 73–82 (1999).
   PubMedGoogle Scholar
• Sullivan KM, Kansu E, Storer B et al. Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transplantation. Biol. Blood Marrow Transplant.4(1), 20–26 (1998).
   PubMedGoogle Scholar
• Winston DJ, Antin JH, Wolff SN et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant.28(2), 187–196 (2001).
   PubMed Web of Science ®Google Scholar
• Ohlsson A, Lacy J. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst. Rev. (3), CD001239 (2010).
   Google Scholar
• Cohen-Wolkowiez M, Benjamin DK Jr, Capparelli E. Immunotherapy in neonatal sepsis: advances in treatment and prophylaxis. Curr. Opin. Pediatr.21(2), 177–181 (2009).
   PubMed Web of Science ®Google Scholar
• Forsyth BW. Primary care of children with HIV infection. Curr. Opin. Pediatr.7(5), 502–512 (1995).
   PubMedGoogle Scholar
• Cikurel K, Schiff L, Simpson DM. Pilot study of intravenous immunoglobulin in HIV-associated myelopathy. AIDS Patient Care STDS23(2), 75–78 (2009).
   PubMedGoogle Scholar
• Lindkvist A, Eden A, Norstrom MM et al. Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. AIDS Res. Ther.6, 15 (2009).
   PubMedGoogle Scholar
• de Sanctis JT, Cumbo-Nacheli G, Dobbie D, Baumgartner D. HIV-associated nemaline rod myopathy: role of intravenous immunoglobulin therapy in two persons with HIV/AIDS. AIDS Read.18(2), 90–94 (2008).
   PubMedGoogle Scholar
• Huang LC, Myer L, Jaspan HB. The role of polyclonal intravenous immunoglobulin in treating HIV-infected children with severe bacterial infections: a retrospective cohort study. BMC Infect. Dis.8, 127 (2008).
   PubMedGoogle Scholar
• Church JA, Fox S, Gomperts E. Effects of high-dose intravenous immunoglobulin on virus load in HIV-infected children. J. Acquir. Immune Defic. Syndr.22(3), 309–311 (1999).
   PubMedGoogle Scholar
• Grisaru-Soen G, Lau W, Arneson C et al. Randomized controlled trial of short-term withdrawal of i.v. immunoglobulin therapy for selected children with human immunodeficiency virus infection. Pediatr. Int.49(6), 972–977 (2007).
   PubMed Web of Science ®Google Scholar
• Coggeshall KM. Inhibitory signaling by B cell Fc γ RIIb. Curr. Opin. Immunol.10(3), 306–312 (1998).
   PubMed Web of Science ®Google Scholar
• Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N. Engl. J. Med.345(10), 747–755 (2001).
   PubMed Web of Science ®Google Scholar
• Hurez V, Kaveri SV, Mouhoub A et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther. Immunol.1(5), 269–277 (1994).
   PubMedGoogle Scholar
• Kaveri S, Vassilev T, Hurez V et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J. Clin. Invest.97(3), 865–869 (1996).
   PubMed Web of Science ®Google Scholar
• Molgo M, Carreno N, Hoyos-Bachiloglu R, Andresen M, Gonzalez S. Use of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis and Stevens–Johnson/toxic epidermal necrolysis overlap syndrome. Review of 15 cases. Rev. Med. Chil.137(3), 383–389 (2009).
   PubMed Web of Science ®Google Scholar
• Horwitz MS, Sarvetnick N. Viruses, host responses, and autoimmunity. Immunol. Rev.169, 241–253 (1999).
   PubMed Web of Science ®Google Scholar
• Guilpain P, Chanseaud Y, Tamby MC et al. Immunomodulatory effects of intravenous immunoglobulins. Presse Med.33(17), 1183–1194 (2004).
   PubMedGoogle Scholar
• Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J. Clin. Invest.84(6), 1974–1981 (1989).
   PubMed Web of Science ®Google Scholar
• Mouthon L, Lacroix-Desmazes S, Pashov A, Kaveri SV, Kazatchkine MD. Immunomodulatory effects of intravenous immunoglobulins in autoimmune diseases. Rev. Med. Interne.20(Suppl. 4), 423S–430S (1999).
   Google Scholar
• Sapir T, Blank M, Shoenfeld Y. Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss. Ann. NY Acad. Sci.1051, 743–778 (2005).
   PubMed Web of Science ®Google Scholar
• Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am. J. Cardiol.95(11A), 17C–23C; discussion 38C–40C (2005).
   Google Scholar
• Udi N, Yehuda S. Intravenous immunoglobulin – indications and mechanisms in cardiovascular diseases. Autoimmun. Rev.7(6), 445–452 (2008).
   PubMedGoogle Scholar
• Wolf HH, Davies SV, Borte M et al. Efficacy, tolerability, safety and pharmacokinetics of a nanofiltered intravenous immunoglobulin: studies in patients with immune thrombocytopenic purpura and primary immunodeficiencies. Vox. Sang.84(1), 45–53 (2003).
   PubMed Web of Science ®Google Scholar
• Tellier Z, Mouthon L. Therapeutic indications of intravenous immunoglobulins. Transfus. Clin. Biol.10(3), 179–184 (2003).
   PubMedGoogle Scholar
• Grenouillet-Delacrea M, Longy-Boursier M. Human immunoglobulins, adverse drug reaction, prevention. Rev. Med. Interne29(2), 24–28 (2008).
   PubMedGoogle Scholar
• Howman RA, Barr AL, Shand AW, Dickinson JE. Antenatal intravenous immunoglobulin in chronic immune thrombocytopenic purpura: case report and literature review. Fetal Diagn. Ther.25(1), 93–97 (2009).
   PubMedGoogle Scholar
• Robak T, Salama A, Kovaleva L et al. Efficacy and safety of PrIVIgen, a novel liquid intravenous immunoglobulin formulation, in adolescent and adult patients with chronic immune thrombocytopenic purpura. Hematology14(4), 227–236 (2009).
   PubMed Web of Science ®Google Scholar
• Tavil B, Unal S, Aytac-Elmas S, Yetgin S. Weekly long-term intravenous immunoglobulin for refractory parvovirus B19 and Epstein–Barr virus-induced immune thrombocytopenic purpura. Turk. J. Pediatr.50(1), 74–77 (2008).
   PubMedGoogle Scholar
• Gereige RS, Barrios NJ. Treatment of childhood acute immune thrombocytopenic purpura with high-dose methylprednisolone, intravenous immunoglobulin, or the combination of both. P. R. Health Sci. J.19(1), 15–18 (2000).
   PubMedGoogle Scholar
• Kocak U, Gursel T, Ozturk G. The effect of steroid and intravenous immunoglobulin on thrombopoietin levels in pediatric patients with immune thrombocytopenic purpura. Blood Coagul. Fibrinolysis11(2), 121–125 (2000).
   PubMedGoogle Scholar
• Kierzkowska B, Lipinska J, Baranska D et al. Takayasu’s arteritis mimicking Kawasaki disease in 7-month-old infant, successfully treated with glucocorticosteroids and intravenous immunoglobulins. Rheumatol. Int. DOI: 10.1007/s00296-010-1518-yOnline First™ (2010) (Epub ahead of print).
   PubMedGoogle Scholar
• Khan S, Dore PC, Sewell WA. Both patient characteristics and IVIg product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease. Pediatr. Allergy Immunol.19(2), 186–187 (2008).
   PubMedGoogle Scholar
• Morgan GJ, MacLeod C, Jenkins J, Stewart C, Craig B. IVIg, aspirin, and Kawasaki disease. J. Pediatr.143(2), 280–281; author reply 281 (2003).
   PubMedGoogle Scholar
• Sakata K, Hamaoka K, Ozawa S et al. A randomized prospective study on the use of 2 g-IVIg or 1 g-IVIg as therapy for Kawasaki disease. Eur. J. Pediatr.166(6), 565–571 (2007).
   PubMedGoogle Scholar
• Soltner E, Neel A, Tiab M et al. Chronic, eventually fatal, Kawasaki-like disease in an adult with spondylarthropathy responding to IVIg therapy. Joint Bone Spine76(5), 559–561 (2009).
   PubMedGoogle Scholar
• Takatsuki S, Ito Y, Takeuchi D et al. IVIg reduced vascular oxidative stress in patients with Kawasaki disease. Circ. J.73(7), 1315–1318 (2009).
   PubMed Web of Science ®Google Scholar
• Suzuki H, Uemura S, Tone S et al. Effects of immunoglobulin and γ-interferon on the production of tumour necrosis factor-α and interleukin-1 β by peripheral blood monocytes in the acute phase of Kawasaki disease. Eur. J. Pediatr.155(4), 291–296 (1996).
   PubMed Web of Science ®Google Scholar
• Bril V, Ilse WK, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain–Barré syndrome. Neurology46(1), 100–103 (1996).
   PubMed Web of Science ®Google Scholar
• Diener HC, Haupt WF, Kloss TM et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange, and immune adsorption in Guillain–Barré syndrome. Eur. Neurol.46(2), 107–109 (2001).
   PubMed Web of Science ®Google Scholar
• Kleyweg RP, van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immunoglobulin and plasma exchange in Guillain–Barré syndrome. Transfus. Sci.15(4), 389–392 (1994).
   PubMedGoogle Scholar
• Hughes RA, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain–Barré syndrome. Cochrane Database Syst. Rev. (1), CD002063 (2006).
   Google Scholar
• Buzzigoli SB, Genovesi M, Lambelet P, Logi C, Raffaelli S, Cattano D. Plasmapheresis treatment in Guillain–Barré syndrome: potential benefit over intravenous immunoglobulin. Anaesth. Intensive Care38(2), 387–389 (2010).
   PubMed Web of Science ®Google Scholar
• Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain–Barré syndrome. Cochrane Database Syst. Rev. (6), CD002063 (2010).
   Google Scholar
• Matsuzawa Y, Sakakibara R, Shoda T, Kishi M, Ogawa E. Good maternal and fetal outcomes of predominantly sensory Guillain–Barré syndrome in pregnancy after intravenous immunoglobulin. Neurol. Sci.31(2), 201–203 (2010).
   PubMedGoogle Scholar
• Mori I, Parizot C, Dorgham K et al. Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain–Barré syndrome. PLoS ONE3(5), e2109 (2008).
   PubMedGoogle Scholar
• Rhee DY, Park GH, Chang SE et al. Pompholyx after intravenous immunoglobulin therapy for treatment of Guillain–Barré syndrome. J. Eur. Acad. Dermatol. Venereol.23(5), 602–604 (2009).
   PubMedGoogle Scholar
• Korinthenberg R, Schessl J, Kirschner J, Monting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain–Barré syndrome: a randomized trial. Pediatrics116(1), 8–14 (2005).
   PubMed Web of Science ®Google Scholar
• Elovaara I, Apostolski S, van Doorn P et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur. J. Neurol.15(9), 893–908 (2008).
   PubMed Web of Science ®Google Scholar
• Comi G, Quattrini A, Fazio R, Roveri L. Immunoglobulins in chronic inflammatory demyelinating polyneuropathy. Neurol. Sci.24(Suppl. 4), S246–S250 (2003).
   Google Scholar
• Blackhouse G, Gaebel K, Xie F et al. Cost-utility of intravenous immunoglobulin (IVIg) compared with corticosteroids for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in Canada. Cost Eff. Resour. Alloc.8, 14 (2010).
   PubMedGoogle Scholar
• Kubori T, Mezaki T, Kaji R et al. The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. No To Shinkei51(2), 127–135 (1999).
   PubMedGoogle Scholar
• Jann S, Bramerio MA, Facchetti D, Sterzi R. Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up. J. Neurol. Neurosurg. Psychiatry80(1), 70–73 (2009).
   PubMed Web of Science ®Google Scholar
• Sladky JT. What is the best initial treatment for childhood chronic inflammatory demyelinating polyneuropathy: corticosteroids or intravenous immunoglobulin? Muscle Nerve38(6), 1638–1643 (2008).
   PubMedGoogle Scholar
• Nobile-Orazio E, Gallia F, Tuccillo F, Terenghi F. Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update. Curr. Opin. Neurol.23(5), 519–523 (2010).
   PubMedGoogle Scholar
• Donofrio PD, Bril V, Dalakas MC et al. Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy. Arch. Neurol.67(9), 1082–1088 (2010).
   PubMedGoogle Scholar
• Kuitwaard K, van den Berg LH, Vermeulen M et al. Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J. Neurol. Neurosurg. Psychiatry81(12), 1374–1379 (2010).
   PubMed Web of Science ®Google Scholar
• Latov N, Deng C, Dalakas MC et al. Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch. Neurol.67(7), 802–807 (2010).
   PubMedGoogle Scholar
• Boerio D, Creange A, Hogrel JY, Gueguen A, Bertrand D, Lefaucheur JP. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy. J. Neurol. Sci.292(1–2), 63–71 (2010).
   PubMedGoogle Scholar
• van der Pol WL, Cats EA, van den Berg LH. Intravenous immunoglobulin treatment in multifocal motor neuropathy. J. Clin. Immunol.30(Suppl. 1), S79–S83 (2010).
   Google Scholar
• Harbo T, Andersen H, Hess A, Hansen K, Sindrup SH, Jakobsen J. Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial. Eur. J. Neurol.16(5), 631–638 (2009).
   PubMed Web of Science ®Google Scholar
• Leger JM, Viala K, Cancalon F et al. Intravenous immunoglobulin as short- and long-term therapy of multifocal motor neuropathy: a retrospective study of response to IVIg and of its predictive criteria in 40 patients. J. Neurol. Neurosurg. Psychiatry79(1), 93–96 (2008).
   PubMed Web of Science ®Google Scholar
• Eftimov F, Vermeulen M, de Haan RJ, van den Berg LH, van Schaik IN. Subcutaneous immunoglobulin therapy for multifocal motor neuropathy. J. Peripher. Nerv. Syst.14(2), 93–100 (2009).
   PubMed Web of Science ®Google Scholar
• Bayry J, Lacroix-Desmazes S, Kaveri SV. Novel therapeutic strategies for multiple sclerosis: potential of intravenous immunoglobulin. Nat. Rev. Drug Discov.8(7), 594 (2009).
   PubMedGoogle Scholar
• Cohen JA. How effective is intravenous immunoglobulin for the treatment of relapsing–remitting multiple sclerosis? Nat. Clin. Pract. Neurol.4(11), 588–589 (2008).
   PubMedGoogle Scholar
• Pohlau D, Przuntek H, Sailer M et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult. Scler.13(9), 1107–1117 (2007).
   PubMed Web of Science ®Google Scholar
• Schwarz S, Meinck HM, Storch-Hagenlocher B. Intravenous immunoglobulins in multiple sclerosis. An update. Nervenarzt80(8), 918–928 (2009).
   PubMedGoogle Scholar
• Liu JF, Wang WX, Xue J et al. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Ther. Apher. Dial.14(2), 153–160 (2010).
   PubMed Web of Science ®Google Scholar
• Pittayanon R, Treeprasertsuk S, Phanthumchinda K. Plasmapheresis or intravenous immunoglobulin for myasthenia gravis crisis in King Chulalongkorn Memorial Hospital. J. Med. Assoc. Thai.92(4), 478–482 (2009).
   PubMedGoogle Scholar
• Gajdos P, Chevret S. Treatment of myasthenia gravis acute exacerbations with intravenous immunoglobulin. Ann. NY Acad. Sci.1132, 271–275 (2008).
   PubMedGoogle Scholar
• Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst. Rev. (1), CD002277 (2008).
   Google Scholar
• Jensen P, Bril V. A comparison of the effectiveness of intravenous immunoglobulin and plasma exchange as preoperative therapy of myasthenia gravis. J. Clin. Neuromuscul. Dis.9(3), 352–355 (2008).
   PubMedGoogle Scholar
• Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Presynaptic effects of immunoglobulin G from patients with Lambert–Eaton myasthenic syndrome: their neutralization by intravenous immunoglobulins. Muscle Nerve31(4), 487–494 (2005).
   PubMed Web of Science ®Google Scholar
• Peterlin BL, Flood W, Kothari MJ. Use of intravenous immunoglobulin in Lambert–Eaton myasthenic syndrome. J. Am. Osteopath. Assoc.102(12), 682–684 (2002).
   PubMedGoogle Scholar
• Gerschlager W, Brown P. Effect of treatment with intravenous immunoglobulin on quality of life in patients with stiff-person syndrome. Mov. Disord.17(3), 590–593 (2002).
   PubMedGoogle Scholar
• Mikaeloff Y, Jambaque I, Mayer M, Ponsot G, Kalifa G, Carel JC. Benefit of intravenous immunoglobulin in autoimmune stiff-person syndrome in a child. J. Pediatr.139(2), 340 (2001).
   PubMedGoogle Scholar
• Shiraishi H, Motomura M, Iwanaga H et al. Successful treatment in a patient with a focal form of stiff-person syndrome using plasma exchange and intravenous immunoglobulin therapy. Rinsho Shinkeigaku42(8), 766–770 (2002).
   PubMedGoogle Scholar
• Overell JR, Hsieh ST, Odaka M, Yuki N, Willison HJ. Treatment for Fisher syndrome, Bickerstaff’s brainstem encephalitis and related disorders. Cochrane Database Syst. Rev. (1), CD004761 (2007).
   Google Scholar
• Mori M, Kuwabara S, Fukutake T, Hattori T. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology68(14), 1144–1146 (2007).
   PubMed Web of Science ®Google Scholar
• Bennetto LP, Lyons P. Miller Fisher syndrome associated with pasteurella multocida infection. J. Neurol. Neurosurg. Psychiatry75(12), 1786–1787 (2004).
   PubMedGoogle Scholar
• Kaushik P, Cohen AJ, Zuckerman SJ et al. Miller fisher variant of Guillain–Barré syndrome requiring a cardiac pacemaker in a patient on tacrolimus after liver transplantation. Ann. Pharmacother.39(6), 1124–1127 (2005).
   PubMed Web of Science ®Google Scholar
• Comi G, Roveri L, Swan A et al. A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J. Neurol.249(10), 1370–1377 (2002).
   PubMed Web of Science ®Google Scholar
• Gorson KC, Ropper AH, Weinberg DH, Weinstein R. Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch. Neurol.59(5), 766–772 (2002).
   PubMed Web of Science ®Google Scholar
• Kizawa M, Mori K, Iijima M, Koike H, Hattori N, Sobue G. Intravenous immunoglobulin treatment in painful sensory neuropathy without sensory ataxia associated with Sjogren’s syndrome. J. Neurol. Neurosurg. Psychiatry77(8), 967–969 (2006).
   PubMedGoogle Scholar
• Taguchi Y, Takashima S, Takata M, Dougu N, Asaoka E, Inoue H. High-dose intravenous immunoglobulin in the treatment of sensory ataxic neuropathy with Sjogren’s syndrome: a case report. No To Shinkei56(5), 421–424 (2004).
   PubMedGoogle Scholar
• Levy Y, Uziel Y, Zandman GG et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. Ann. Rheum. Dis.62(12), 1221–1223 (2003).
   PubMed Web of Science ®Google Scholar
• Tsurikisawa N, Taniguchi M, Saito H et al. Treatment of Churg–Strauss syndrome with high-dose intravenous immunoglobulin. Ann. Allergy Asthma Immunol.92(1), 80–87 (2004).
   PubMed Web of Science ®Google Scholar
• Nobuhara Y, Saito M, Goto R et al. Chronic progressive sensory ataxic neuropathy associated with limited systemic sclerosis. J. Neurol. Sci.241(1–2), 103–106 (2006).
   PubMedGoogle Scholar
• Carpo M, Meucci N, Allaria S et al. Anti-sulfatide IgM antibodies in peripheral neuropathy. J. Neurol. Sci.176(2), 144–150 (2000).
   PubMed Web of Science ®Google Scholar
• Heaney D, Geddes JF, Nagendren K, Swash M. Sarcoid polyneuropathy responsive to intravenous immunoglobulin. Muscle Nerve29(3), 447–450 (2004).
   PubMedGoogle Scholar
• Ponsford S, Willison H, Veitch J, Morris R, Thomas PK. Long-term clinical and neurophysiological follow-up of patients with peripheral, neuropathy associated with benign monoclonal gammopathy. Muscle Nerve23(2), 164–174 (2000).
   PubMed Web of Science ®Google Scholar
• Gondim FA, Brannagan TH 3rd, Sander HW, Chin RL, Latov N. Peripheral neuropathy in patients with inflammatory bowel disease. Brain128(Pt 4), 867–879 (2005).
   PubMed Web of Science ®Google Scholar
• Caporale CM, Capasso M, Ragno M, Di Muzio A, Uncini A. Lewis–Sumner syndrome in hepatitis C virus infection: a possible pathogenetic association with therapeutic problems. Muscle Nerve34(1), 116–121 (2006).
   PubMedGoogle Scholar
• Odum J, D’Costa D, Freeth M, Taylor D, Smith N, MacWhannell A. Cryoglobulinaemic vasculitis caused by intravenous immunoglobulin treatment. Nephrol. Dial. Transplant16(2), 403–406 (2001).
   PubMed Web of Science ®Google Scholar
• Vrancken AF, Notermans NC, Jansen GH, Wokke JH, Said G. Progressive idiopathic axonal neuropathy – a comparative clinical and histopathological study with vasculitic neuropathy. J. Neurol.251(3), 269–278 (2004).
   PubMedGoogle Scholar
• Gorson KC, Ropper AH. Idiopathic distal small fiber neuropathy. Acta Neurol. Scand.92(5), 376–382 (1995).
   PubMedGoogle Scholar
• Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology48(3), 712–716 (1997).
   PubMed Web of Science ®Google Scholar
• Nakajima M, Fujioka S, Ohno H, Iwamoto K. Partial but rapid recovery from paralysis after immunomodulation during early stage of neuralgic amyotrophy. Eur. Neurol.55(4), 227–229 (2006).
   PubMedGoogle Scholar
• Takakura Y, Murai H, Furuya H, Ochi H, Kira J. A case of brachial amyotrophic diplegia accompanied with Sjogren’s syndrome presenting good response to immunotherapies in the early course of the disease. Rinsho Shinkeigaku45(5), 346–350 (2005).
   PubMedGoogle Scholar
• Pascoe MK, Low PA, Windebank AJ, Litchy WJ. Subacute diabetic proximal neuropathy. Mayo Clin. Proc.72(12), 1123–1132 (1997).
   PubMedGoogle Scholar
• Fernandes Filho JA, Nathan BM, Palmert MR, Katirji B. Diabetic amyotrophy in an adolescent responsive to intravenous immunoglobulin. Muscle Nerve32(6), 818–820 (2005).
   PubMedGoogle Scholar
• Morii T, Fujita H, Toyoshima I, Sageshima M, Ito S. Efficacy of immunoglobulin and prednisolone in diabetic amyotrophy. Endocr. J.50(6), 831–832 (2003).
   PubMedGoogle Scholar
• Tellier Z, Andre MH, Polack B. Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives. Clin. Rev. Allergy Immunol.37(2), 125–134 (2009).
   PubMedGoogle Scholar
• Gianella-Borradori A, Hirt A, Luthy A, Wagner HP, Imbach P. Haemophilia due to factor VIII inhibitors in a patient suffering from an autoimmune disease: treatment with intravenous immunoglobulin. A case report. Blut48(6), 403–407 (1984).
   PubMedGoogle Scholar
• Seifried E, Gaedicke G, Pindur G, Rasche H. The treatment of haemophilia A inhibitor with high dose intravenous immunoglobulin. Blut48(6), 397–401 (1984).
   PubMedGoogle Scholar
• Hoppe B, Gaedicke G, Kiesewetter H, Salama AR. Response to intravenous immunoglobulin G in an infant with immunoglobulin A-associated autoimmune haemolytic anaemia. Vox. Sang.86(2), 151–153 (2004).
   PubMedGoogle Scholar
• Macintyre EA, Linch DC, Macey MG, Newland AC. Successful response to intravenous immunoglobulin in autoimmune haemolytic anaemia. Br. J. Haematol.60(2), 387–388 (1985).
   PubMedGoogle Scholar
• Majer RV, Hyde RD. High-dose intravenous immunoglobulin in the treatment of autoimmune haemolytic anaemia. Clin. Lab. Haematol.10(4), 391–395 (1988).
   PubMedGoogle Scholar
• Murakami H, Kikuchi M, Toyama K, Ikeda Y. A case of autoimmune neutropenia and thrombocytopenia – effect of high-dose intravenous immunoglobulin. Keio J. Med.34(4), 227–232 (1985).
   PubMedGoogle Scholar
• Baum S, Scope A, Barzilai A, Azizi E, Trau H. The role of IVIg treatment in severe pemphigus vulgaris. J. Eur. Acad. Dermatol. Venereol.20(5), 548–552 (2006).
   PubMed Web of Science ®Google Scholar
• Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity39(7), 601–607 (2006).
   PubMed Web of Science ®Google Scholar
• Ishii N, Hashimoto T, Zillikens D, Ludwig RJ. High-dose intravenous immunoglobulin (IVIg) therapy in autoimmune skin blistering diseases. Clin. Rev. Allergy Immunol.38(2–3), 186–195 (2010).
   PubMed Web of Science ®Google Scholar
• Kasperkiewicz M, Schmidt E. Current treatment of autoimmune blistering diseases. Curr. Drug Discov. Technol.6(4), 270–280 (2009).
   PubMedGoogle Scholar
• Roujeau JC, Ingen-Housz-Oro S, Leroux C, Joly P. Treatment of bullous pemphigoid and pemphigus. The French experience, 2009 update. G. Ital. Dermatol. Venereol.144(4), 333–338 (2009).
   PubMedGoogle Scholar
• Cherin P. Intravenous immunoglobulins in the treatment of polymyositis and dermatomyositis. Ann. Med. Interne (Paris)151(Suppl. 1), 1S48–1S50 (2000).
   PubMedGoogle Scholar
• Cherin P, Herson S. Intravenous immunoglobulins in polymyositis and dermatomyositis. Rev. Med. Interne20(Suppl. 4), 436S–439S (1999).
   Google Scholar
• Luzi G, Diamanti AP, Germano V et al. Successful treatment with intravenous immunoglobulins in a patient affected by dermatomyositis/systemic lupus erythematosus overlap syndrome and tuberculosis. Clin. Immunol.125(2), 127–130 (2007).
   PubMedGoogle Scholar
• Marie I, Hachulla E, Levesque H et al. Intravenous immunoglobulins as treatment of life threatening esophageal involvement in polymyositis and dermatomyositis. J. Rheumatol.26(12), 2706–2709 (1999).
   PubMed Web of Science ®Google Scholar
• Mouthon L. Physiopathology of polymyositis and dermatomyositis, mechanism of action of intravenous immunoglobulins. Rev. Med. Interne 25 Spec. No 3, 10–12 (2004).
   PubMedGoogle Scholar
• Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A. Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun. Rev.10(3), 144–149 (2010).
   PubMedGoogle Scholar
• O’Neil KM. Progress in pediatric vasculitis. Curr. Opin. Rheumatol.21(5), 538–546 (2009).
   PubMedGoogle Scholar
• Yazici Y. Systemic vasculitis treatment and monitoring update, 2008. Bull. NYU Hosp. Jt. Dis.66(3), 228–230 (2008).
   PubMedGoogle Scholar
• Zandman-Goddard G, Blank M, Shoenfeld Y. Intravenous immunoglobulins in systemic lupus erythematosus: from the bench to the bedside. Lupus18(10), 884–888 (2009).
   PubMed Web of Science ®Google Scholar
• Karim MY, Pisoni CN, Khamashta MA. Update on immunotherapy for systemic lupus erythematosus – what’s hot and what’s not! Rheumatology (Oxford)48(4), 332–341 (2009).
   PubMed Web of Science ®Google Scholar
• LeHoang P, Cassoux N, George F, Kullmann N, Kazatchkine MD. Intravenous immunoglobulin (IVIg) for the treatment of birdshot retinochoroidopathy. Ocul. Immunol. Inflamm.8(1), 49–57 (2000).
   PubMed Web of Science ®Google Scholar
• Tellier Z. Human immunoglobulins in intraocular inflammation. Ann. NY Acad. Sci.1110, 337–347 (2007).
   PubMed Web of Science ®Google Scholar
• Phan TG, Wong RC, Crotty K, Adelstein S. Toxic epidermal necrolysis in acquired immunodeficiency syndrome treated with intravenous gammaglobulin. Australas. J. Dermatol.40(3), 153–157 (1999).
   PubMedGoogle Scholar
• Andresen M, Boghero Y, Molgo M, Dougnao A, Diaz O. Toxic epidermal necrolysis. Therapy in ICU with intravenous immunoglobulins in a case. Rev. Med. Chil.128(12), 1343–1348 (2000).
   PubMedGoogle Scholar
• Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br. J. Plast. Surg.58(4), 504–510 (2005).
   PubMedGoogle Scholar
• Mangla K, Rastogi S, Goyal P, Solanki RB, Rawal RC. Efficacy of low dose intravenous immunoglobulins in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J. Dermatol. Venereol. Leprol.71(6), 398–400 (2005).
   PubMedGoogle Scholar
• Stella M, Clemente A, Bollero D, Risso D, Dalmasso P. Toxic epidermal necrolysis (TEN) and Stevens–Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns33(4), 452–459 (2007).
   PubMed Web of Science ®Google Scholar
• Tan AW, Thong BY, Yip LW, Chng HH, Ng SK. High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. J. Dermatol.32(1), 1–6 (2005).
   PubMedGoogle Scholar
• Yuste M, Sanchez-Estella J, Santos JC et al. Stevens–Johnson syndrome/toxic epidermal necrolysis treated with intravenous immunoglobulins. Actas Dermosifiliogr.96(9), 589–592 (2005).
   PubMedGoogle Scholar
• Constantinescu D, Cozmei C, Dumitrascu I, Carasevici E. The management of unexplained recurrent abortions. Is immunotherapy an option? Rev. Med. Chir. Soc. Med. Nat. Iasi.112(2), 371–378 (2008).
   PubMedGoogle Scholar
• Carp HJ. Intravenous immunoglobulin: effect on infertility and recurrent pregnancy loss. Isr. Med. Assoc. J.9(12), 877–880 (2007).
   PubMedGoogle Scholar
• Wegmann M, Hauber HP. Experimental approaches towards allergic asthma therapy-murine asthma models. Recent Pat. Inflamm. Allergy Drug Discov.4(1), 37–53 (2010).
   PubMedGoogle Scholar
• Kovalev IE, Kovaleva VL, Rumiantseva EI. Mechanisms of the therapeutic effect of immunoglobulins in the treatment of bronchial asthma. Eksp. Klin. Farmakol.71(5), 48–51 (2008).
   PubMedGoogle Scholar
• Burnett AM, Domachowske JB. Therapeutic considerations for children with invasive group A streptococcal infections: a case series report and review of the literature. Clin. Pediatr. (Phila.)46(6), 550–555 (2007).
   PubMedGoogle Scholar
• Schwartz-Albiez R, Monteiro RC, Rodriguez M, Binder CJ, Shoenfeld Y. Natural antibodies, intravenous immunoglobulin and their role in autoimmunity cancer and inflammation. Clin. Exp. Immunol.158(Suppl. 1), S43–S50 (2009).
   PubMed Web of Science ®Google Scholar
• Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann. Intern. Med.93(1), 55–56 (1980).
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C, Siegal FP, Smithwick EM et al. Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann. Intern. Med.101(4), 435–439 (1984).
   PubMed Web of Science ®Google Scholar
• Quartier P, Debre M, De Blic J et al. Early and prolonged intravenous immunoglobulin replacement therapy in childhood agammaglobulinemia: a retrospective survey of 31 patients. J. Pediatr.134(5), 589–596 (1999).
   PubMed Web of Science ®Google Scholar
• Webb DB, Kendra JR, Gross E, Stamatakis JD. Infusion of intravenous immunoglobulin via implantable subcutaneous catheter. Lancet337(8757), 1617–1618 (1991).
   PubMedGoogle Scholar
• Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch. Dis. Child.79(1), 48–51 (1998).
   PubMed Web of Science ®Google Scholar
• Arora R, Newton TC, Nelson MR. Subcutaneous immunoglobulin therapy in an 11-year-old patient with common variable immunodeficiency and von Willebrand disease. Ann. Allergy Asthma Immunol.99(4), 367–370 (2007).
   PubMedGoogle Scholar
• Gardulf A, Hammerstrom L, Smith CI. Hometreatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet338, 162–166 (1991).
   PubMed Web of Science ®Google Scholar
• Thomas MJ, Brennan VM, Chapel HH. Rapid subcutaneous immunoglobulin infusions in children. Lancet342(8884), 1432–1433 (1993).
   PubMed Web of Science ®Google Scholar
• Abrahamsen TG, Sandersen H, Bustnes A. Home therapy with subcutaneous immunoglobulin infusions in children with congenital immunodeficiencies. Pediatrics98(6 Pt 1), 1127–1131 (1996).
   PubMedGoogle Scholar
• Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J. Clin. Immunol.20(2), 94–100 (2000).
   PubMed Web of Science ®Google Scholar
• Nicolay U, Kiessling P, Berger M et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J. Clin. Immunol.26(1), 65–72 (2006).
   PubMed Web of Science ®Google Scholar
• Gardulf A, Nicolay U. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr. Opin. Allergy Clin. Immunol.6(6), 434–442 (2006).
   PubMed Web of Science ®Google Scholar
• Moore ML, Quinn JM. Subcutaneous immunoglobulin replacement therapy for primary antibody deficiency: advancements into the 21st Century. Ann. Allergy Asthma Immunol.101(2), 114–121; quiz 122–113, 178 (2008).
   PubMed Web of Science ®Google Scholar
• Membe SK, Ho C, Cimon K, Morrison A, Kanani A, Roifman CM. Economic assessment of different modalities of immunoglobulin replacement therapy. Immunol. Allergy Clin. North Am.28(4), 861–874, x (2008).
   PubMed Web of Science ®Google Scholar
• Gardulf A, Andersen V, Bjorkander J et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet345(8946), 365–369 (1995).
   PubMed Web of Science ®Google Scholar
• Hogy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur. J. Health Econ.6(1), 24–29 (2005).
   PubMedGoogle Scholar
• Haddad L, Perrinet M, Parent D et al. Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution. Rev. Med. Interne.27(12), 924–926 (2006).
   PubMed Web of Science ®Google Scholar
• Misbah S, Sturzenegger MH, Borte M et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin. Exp. Immunol.158(Suppl. 1), S51–S59 (2009).
   PubMedGoogle Scholar